Terms: = Skin cancer AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Treatment
63 results:
1. Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma.
Eroglu Z; Chen YA; Smalley I; Li J; Markowitz JK; Brohl AS; Tetteh L; Taylor H; Sondak VK; Khushalani NI; Smalley KSM
Cancer; 2024 Jan; 130(2):232-243. PubMed ID: 37776537
[TBL] [Abstract] [Full Text] [Related]
2. Identification of circRNA-miRNA-mRNA Network Regulated by hsp90 in Human Melanoma A375 Cells.
Fu Q; Gao H; Liu K; Su J; Zhang J; Guo X; Yang F
Comb Chem High Throughput Screen; 2024; 27(2):307-316. PubMed ID: 37303182
[TBL] [Abstract] [Full Text] [Related]
3. In Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity.
Ma S; Huis In't Veld RV; Houy A; Stern MH; Rich C; Ossendorp FA; Jager MJ
Invest Ophthalmol Vis Sci; 2023 Jun; 64(7):10. PubMed ID: 37272766
[TBL] [Abstract] [Full Text] [Related]
4. SK119, a Novel Shikonin Derivative, Leads to Apoptosis in Melanoma Cell Lines and Exhibits Synergistic Effects with Vemurafenib and Cobimetinib.
Kretschmer N; Durchschein C; Hufner A; Rinner B; Lohberger B; Bauer R
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628494
[TBL] [Abstract] [Full Text] [Related]
5. hsp90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
Sasame J; Ikegaya N; Kawazu M; Natsumeda M; Hayashi T; Isoda M; Satomi K; Tomiyama A; Oshima A; Honma H; Miyake Y; Takabayashi K; Nakamura T; Ueno T; Matsushita Y; Iwashita H; Kanemaru Y; Murata H; Ryo A; Terashima K; Yamanaka S; Fujii Y; Mano H; Komori T; Ichimura K; Cahill DP; Wakimoto H; Yamamoto T; Tateishi K
Clin Cancer Res; 2022 Jun; 28(11):2425-2439. PubMed ID: 35344043
[TBL] [Abstract] [Full Text] [Related]
6. hsp90/IKK-rich small extracellular vesicles activate pro-angiogenic melanoma-associated fibroblasts via the NF-κB/CXCL1 axis.
Tang H; Zhou X; Zhao X; Luo X; Luo T; Chen Y; Liang W; Jiang E; Liu K; Shao Z; Shang Z
Cancer Sci; 2022 Apr; 113(4):1168-1181. PubMed ID: 35043517
[TBL] [Abstract] [Full Text] [Related]
7. Quercetin increases mitochondrial proteins (VDAC and SDH) and downmodulates AXL and PIM-1 tyrosine kinase receptors in NRAS melanoma cells.
Rocha-Brito KJP; Clerici SP; Cordeiro HG; Scotá Ferreira AP; Barreto Fonseca EM; Gonçalves PR; Abrantes JLF; Milani R; Massaro RR; Maria-Engler SS; Ferreira-Halder CV
Biol Chem; 2022 Feb; 403(3):293-303. PubMed ID: 34854272
[TBL] [Abstract] [Full Text] [Related]
8. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) sensitize melanoma cells to MEK inhibition and inhibit metastasis and relapse by inducing degradation of AXL.
Chen Y; Zhang Y; Chen S; Liu W; Lin Y; Zhang H; Yu F
Pigment Cell Melanoma Res; 2022 Mar; 35(2):238-251. PubMed ID: 34748282
[TBL] [Abstract] [Full Text] [Related]
9. hsp90 inhibitors reduce cholesterol storage in Niemann-Pick type C1 mutant fibroblasts.
Pipalia NH; Saad SZ; Subramanian K; Cross A; Al-Motawa A; Garg K; Blagg BSJ; Neckers L; Helquist P; Wiest O; Ory DS; Maxfield FR
J Lipid Res; 2021; 62():100114. PubMed ID: 34481829
[TBL] [Abstract] [Full Text] [Related]
10. A novel C-terminal hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas.
Sanchez JN; Subramanian C; Chanda M; Shanguan G; Zhang N; Wang T; Timmermann BN; Blagg BSJ; Cohen MS
Melanoma Res; 2021 Jun; 31(3):197-207. PubMed ID: 33904516
[TBL] [Abstract] [Full Text] [Related]
11. Sulfoxythiocarbamate S-4 inhibits hsp90 in human cutaneous squamous cell carcinoma cells.
Zhang Y; VanHecke GC; Ahn YH; Proby CM; Dinkova-Kostova AT
Eur J Pharmacol; 2020 Dec; 889():173609. PubMed ID: 33031796
[TBL] [Abstract] [Full Text] [Related]
12. Inhibitors of hsp90 in melanoma.
Mielczarek-Lewandowska A; Hartman ML; Czyz M
Apoptosis; 2020 Feb; 25(1-2):12-28. PubMed ID: 31659567
[TBL] [Abstract] [Full Text] [Related]
13. Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling.
Fleming V; Hu X; Weller C; Weber R; Groth C; Riester Z; Hüser L; Sun Q; Nagibin V; Kirschning C; Bronte V; Utikal J; Altevogt P; Umansky V
Cancer Res; 2019 Sep; 79(18):4715-4728. PubMed ID: 31337655
[TBL] [Abstract] [Full Text] [Related]
14. Tetra-substituted pyrrole derivatives act as potent activators of p53 in melanoma cells.
Proto MC; Fiore D; Forte G; Cuozzo P; Ramunno A; Fattorusso C; Gazzerro P; Pascale M; Franceschelli S
Invest New Drugs; 2020 Jun; 38(3):634-649. PubMed ID: 31240514
[TBL] [Abstract] [Full Text] [Related]
15. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
[TBL] [Abstract] [Full Text] [Related]
16. Results from phase II trial of hsp90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
Shah S; Luke JJ; Jacene HA; Chen T; Giobbie-Hurder A; Ibrahim N; Buchbinder EL; McDermott DF; Flaherty KT; Sullivan RJ; Lawrence DP; Ott PA; Hodi FS
Melanoma Res; 2018 Dec; 28(6):605-610. PubMed ID: 30211813
[TBL] [Abstract] [Full Text] [Related]
17. Combined BRAF and hsp90 Inhibition in Patients with Unresectable
Eroglu Z; Chen YA; Gibney GT; Weber JS; Kudchadkar RR; Khushalani NI; Markowitz J; Brohl AS; Tetteh LF; Ramadan H; Arnone G; Li J; Zhao X; Sharma R; Darville LNF; Fang B; Smalley I; Messina JL; Koomen JM; Sondak VK; Smalley KSM
Clin Cancer Res; 2018 Nov; 24(22):5516-5524. PubMed ID: 29674508
[No Abstract] [Full Text] [Related]
18. Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors.
Wahid M; Jawed A; Mandal RK; Dar SA; Akhter N; Somvanshi P; Khan F; Lohani M; Areeshi MY; Haque S
Crit Rev Oncol Hematol; 2018 May; 125():84-88. PubMed ID: 29650281
[TBL] [Abstract] [Full Text] [Related]
19. Targeting CDK2 overcomes melanoma resistance against BRAF and hsp90 inhibitors.
Azimi A; Caramuta S; Seashore-Ludlow B; Boström J; Robinson JL; Edfors F; Tuominen R; Kemper K; Krijgsman O; Peeper DS; Nielsen J; Hansson J; Egyhazi Brage S; Altun M; Uhlen M; Maddalo G
Mol Syst Biol; 2018 Mar; 14(3):e7858. PubMed ID: 29507054
[TBL] [Abstract] [Full Text] [Related]
20. Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative hsp90 Inhibitors.
Bizarro A; Sousa D; Lima RT; Musso L; Cincinelli R; Zuco V; De Cesare M; Dallavalle S; Vasconcelos MH
Molecules; 2018 Feb; 23(2):. PubMed ID: 29438315
[TBL] [Abstract] [Full Text] [Related]
[Next]
